Pune: Pharma and biotech major Wockhardt has received US FDA nod to launch 25 mg, 50 mg, 100 mg, 200 mg and 300 mg extended release tablets of Lamotrigine, a drug used in the treatment of epilepsy. This is the generic name for the brand Lamictal XR.
The company will be launching the product immediately. The US market for the drug is pegged at $250 million.
Wockhardt will manufacture the extended release tablets at its Aurangabad facility. The technology for extended release tablets was developed in-house, the company said.
No comments:
Post a Comment